JAK-signal transducer and activator of transcription (JAK-STAT) signalling underpins interferon-mediated antiviral defense; pharmacologic JAK inhibition can blunt these pathways and raise susceptibility to serious infection, hence the tofacitinib recommendation to interrupt treatment during active serious infection [10]. The gene discussed is SOAT1; the disease is infection.